AKT1 and early-onset autosomal dominant Alzheimer disease: The GABA-B receptor, which can be proposed as a potential treatment target for Alzheimer’s disease (AD), inhibited oxidative stress damage in the neurons of AD model rats by activating the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway [15] (Figure 1).